Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

An FDA perspective on preclinical development of cell-based regenerative medicine products

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Characteristics of cell-based regenerative medicine products and preclinical testing programs, based on analysis of 163 IND submissions to the FDA/CBER/OCTGT from 2006 to 2013.

References

  1. United States Code Title 21, Section 312.23(a)(8) http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=312.23.

  2. Bailey, A.M. Sci. Transl. Med. 4, 147fs28 (2012).

    Article  Google Scholar 

  3. Mendicino, M., Bailey, A.M., Wonnacott, K., Puri, R.K. & Bauer, S.R. Cell Stem Cell 14, 141–145 (2014).

    CAS  Article  Google Scholar 

  4. Anatol, R. et al. The regulatory process from concept to market. Principles of Tissue Engineering 1781–1797 (Academic Press, 2013).

  5. Robinson, R., Bailey, A.M. & Ibrahim, S. Sci. Transl. Med. 3, 94ec124 (2011).

    Google Scholar 

Download references

Acknowledgements

We thank C. Gacchina Johnson for her contributions to data analysis of regulatory submissions.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Alexander M Bailey, Michael Mendicino or Patrick Au.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bailey, A., Mendicino, M. & Au, P. An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol 32, 721–723 (2014). https://doi.org/10.1038/nbt.2971

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2971

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing